LLY is trading at $950.30 (+3.32%) amid a broad market rally and de-escalation hopes in the Iran conflict.

  • The stock continues to see strength following yesterday's announcement of a $38.00 per share cash acquisition of Centessa Pharmaceuticals and an expanded AI drug discovery partnership.
  • LLY previously surged 4.17% to reach $923.60 on March 31 as investors reacted to the strategic expansion.
  • Today's move aligns with gains in the broader market, including the S&P 500 (+1.02%) and NASDAQ (+1.53%).